BioSyent (RX.V) Stock Price
BioSyent Price
Revenue has compounded at 19.3% per year over the past 19 years to 43.05 M CAD. Earnings per share have grown at 18.2% per year over the last 18 years. BioSyent's net margin stands at 20.9%, down from 21.9% several years earlier. BioSyent currently offers a dividend yield of about 1.28%. The payout ratio is around 17% of earnings. The dividend has grown at 71.0% per year over the past 3 years. Analysts set a median price target of 16.83 CAD, implying 7.5% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. Over the past year BioSyent shares have gained 32.4%. The stock trades about 46% above its 52-week low.
BioSyent stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of BioSyent over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioSyent stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioSyent's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | BioSyent Price |
|---|---|
| 9/10/2026 | 15.65 CAD |
| 9/9/2026 | 15.69 CAD |
| 9/8/2026 | 15.95 CAD |
| 9/4/2026 | 15.97 CAD |
| 9/3/2026 | 15.88 CAD |
| 9/2/2026 | 16.00 CAD |
| 9/1/2026 | 15.87 CAD |
| 8/31/2026 | 15.99 CAD |
| 8/30/2026 | 15.50 CAD |
| 8/28/2026 | 15.81 CAD |
| 8/27/2026 | 16.00 CAD |
| 8/26/2026 | 15.84 CAD |
| 8/25/2026 | 15.70 CAD |
| 8/24/2026 | 15.60 CAD |
| 8/21/2026 | 15.70 CAD |
| 8/20/2026 | 14.75 CAD |
| 8/19/2026 | 15.00 CAD |
| 8/18/2026 | 14.60 CAD |
| 8/17/2026 | 14.60 CAD |
| 8/14/2026 | 15.25 CAD |
| 8/13/2026 | 15.01 CAD |
| 8/12/2026 | 14.80 CAD |
| 8/11/2026 | 15.00 CAD |
| 8/10/2026 | 15.00 CAD |
| 8/7/2026 | 15.00 CAD |
| 8/6/2026 | 15.49 CAD |
| 8/5/2026 | 15.19 CAD |
| 8/4/2026 | 14.65 CAD |
| 7/31/2026 | 14.75 CAD |
| 7/30/2026 | 14.66 CAD |
BioSyent Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
BioSyent Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM CAD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM CAD |
| EBITM CAD |
| EBIT MARGIN% |
| NET INCOMEM CAD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.CAD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.00 | 12.00 | 15.00 | 17.00 | 20.00 | 21.00 | 21.00 | 22.00 | 28.00 | 27.00 | 31.00 | 35.00 | 43.00 | 73.00 | 83.00 | 91.00 |
| 40.00 | 71.43 | 25.00 | 13.33 | 17.65 | 5.00 | – | 4.76 | 27.27 | -3.57 | 14.81 | 12.90 | 22.86 | 69.77 | 13.70 | 9.64 |
| 85.71 | 75.00 | 80.00 | 82.35 | 75.00 | 76.19 | 76.19 | 77.27 | 78.57 | 81.48 | 80.65 | 77.14 | 74.42 | 74.42 | 74.42 | 74.42 |
| 6.00 | 9.00 | 12.00 | 14.00 | 15.00 | 16.00 | 16.00 | 17.00 | 22.00 | 22.00 | 25.00 | 27.00 | 32.00 | 54.33 | 61.77 | 67.72 |
| 2.00 | 4.00 | 5.00 | 5.00 | 6.00 | 6.00 | 5.00 | 5.00 | 8.00 | 6.00 | 7.00 | 9.00 | 11.00 | 15.00 | 16.00 | 19.00 |
| 28.57 | 33.33 | 33.33 | 29.41 | 30.00 | 28.57 | 23.81 | 22.73 | 28.57 | 22.22 | 22.58 | 25.71 | 25.58 | 20.55 | 19.28 | 20.88 |
| 1.00 | 3.00 | 3.00 | 4.00 | 5.00 | 5.00 | 4.00 | 3.00 | 6.00 | 5.00 | 6.00 | 7.00 | 9.00 | 11.00 | 12.00 | 15.00 |
| – | 200.00 | – | 33.33 | 25.00 | – | -20.00 | -25.00 | 100.00 | -16.67 | 20.00 | 16.67 | 28.57 | 22.22 | 9.09 | 25.00 |
| – | – | – | – | – | – | – | – | – | 0.16 | 0.16 | 0.18 | 0.20 | 0.22 | 0.25 | 0.28 |
| – | – | – | – | – | – | – | – | – | – | – | 12.50 | 11.11 | 10.00 | 13.64 | 12.00 |
| 14.33 | 14.49 | 14.49 | 14.52 | 14.54 | 14.39 | 13.58 | 12.93 | 12.67 | 12.10 | 11.74 | 11.59 | 11.59 | 11.59 | 11.59 | 11.59 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales BioSyent generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioSyent retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioSyent's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares BioSyent has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioSyent's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
BioSyent stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
BioSyent Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
BioSyent business model & stock analysis
BioSyent SWOT Analysis
Strengths
Biosyent Inc. has several key strengths that contribute to its competitive advantage and success in the market. These include:
- Strong product portfolio: Biosyent offers a diverse range of pharmaceutical and healthcare products, which enables it to cater to various market segments and meet the needs of a broad customer base.
- Established market presence: With years of experience and a solid reputation, Biosyent has established itself as a trusted and reliable provider of high-quality pharmaceuticals in the industry.
- Strategic partnerships: The company has formed strategic partnerships with key distributors and healthcare professionals, allowing it to effectively reach its target market and expand its customer base.
- Financial stability: Biosyent has a strong financial position, well-managed cash flow, and a robust revenue stream, which provides stability and enables continued investment in research and development.
Weaknesses
Despite its strengths, Biosyent Inc. also has certain weaknesses that pose challenges and areas for improvement:
- Limited global reach: The company's operations are primarily focused on the Canadian market, which limits its exposure to international opportunities and potential for growth.
- Dependence on key products: Biosyent's success is largely dependent on a few core products, making it vulnerable to market fluctuations and increased competition in those specific markets.
- Relatively small size: As a smaller pharmaceutical company, Biosyent may face challenges in terms of resources, market influence, and the ability to compete with larger industry players.
Opportunities
Several opportunities exist for Biosyent Inc. to capitalize on and further strengthen its market position:
- Expansion into new markets: Biosyent can explore potential expansion into international markets, leveraging its strong product portfolio to cater to new customer segments and increase its global footprint.
- Growing healthcare industry: The increasing demand for healthcare products and services presents an opportunity for Biosyent to introduce new products and tap into emerging market trends.
- Strategic collaborations: By establishing partnerships with research institutions and pharmaceutical companies, Biosyent can enhance its research and development capabilities and accelerate product innovation.
Threats
Biosyent Inc. faces certain threats that may impact its growth and market position:
- Market competition: The pharmaceutical industry is highly competitive, and Biosyent faces competition from both established players and new entrants, which can put pressure on pricing and market share.
- Regulatory challenges: Stringent regulations and compliance requirements in the pharmaceutical industry can pose challenges for Biosyent, particularly in terms of product development and approvals.
- Economic and market volatility: Uncertain economic conditions and market fluctuations can impact consumer spending, healthcare budgets, and overall demand for pharmaceutical products.
BioSyent Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
BioSyent historical P/E ratio, EBIT multiple, and P/S ratio
BioSyent annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
BioSyent shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
BioSyent Dividend History
5 years of dividend payments · 3 consecutive increases
BioSyent dividend history and estimates
Max
Details
BioSyent dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current BioSyent forecasts and price targets in September 2026
Analyst Price Targets 2026BioSyent Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 3/19/2024 | 0.10CAD | - | 8.67 MCAD | - | 2023 Q4 |
| 3/7/2023 | 0.12CAD | - | 7.21 MCAD | - | 2022 Q4 |
| 11/8/2022 | 0.13CAD | - | 7.10 MCAD | - | 2022 Q3 |
| 8/23/2022 | 0.14CAD | - | 7.61 MCAD | - | 2022 Q2 |
| 5/18/2022 | 0.11CAD | - | 7.10 MCAD | - | 2022 Q1 |
| 3/8/2022 | 0.11CAD | - | 7.00 MCAD | - | 2021 Q4 |
| 11/18/2021 | 0.10CAD | - | 7.00 MCAD | - | 2021 Q3 |
| 8/25/2021 | 0.10CAD | - | 5.79 MCAD | - | 2021 Q2 |
| 5/27/2021 | 0.09CAD | - | 6.19 MCAD | - | 2021 Q1 |
| 3/17/2021 | 0.08CAD | - | 5.58 MCAD | - | 2020 Q4 |
BioSyent shareholder structure
| % | Name |
|---|---|
1.84985% | |
1.80292% | |
1.32357% | |
0.17184% | |
0.02761% |
BioSyent Beneficial Ownership Filings (SEC 13D/G)
BioSyent Executives and Management Board
14 members · avg. age 62 · 21 % women
Mr. Rene Goehrum (66)
Chairman of the Board, President and Chief Executive Officer · since 1996
761,523.00 CAD
Management
Mr. Robert March
Chief Financial Officer, Vice President - Finance
Mr. Joost Van Der Mark
Vice President- Corporate Development
Mr. Kevin Wilson
Vice President - Sales
Ms. Marnie Mccormick
Vice President and General Manager
Board of Directors
Mr. Navid Ashrafi
Director- Medical and Regulatory Affairs
Mr. Sharan Raghubir
Director - Specialty Sales · since 2022
Mr. Joseph Arcuri (60)
Independent Director · since 2003
Mr. Peter Lockhard (62)
Lead Independent Director
Mr. Stephen Wilton (65)
Independent Director
Ms. Sara Elford (55)
Independent Director
BioSyent Supply Chain
BioSyent Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.65 | -0.60 | — | ||
| 2 | 0.82 | -0.16 | — | ||
| 3 | -0.54 | -0.56 | — |
Frequently asked questions about BioSyent
The business model of Biosyent Inc is focused on acquiring or in-licensing pharmaceutical and healthcare products. The company identifies niche markets with unmet medical needs and seeks regulatory approval to provide branded pharmaceuticals or health products that address those needs. Biosyent Inc aims to improve patient outcomes by offering innovative and effective treatment options in areas such as cardiovascular health, dermatology, neurology, and pediatrics. By partnering with established companies or acquiring the rights to specific products, Biosyent Inc brings affordable and quality medicines to market, providing patients with improved access to vital healthcare solutions.
Biosyent Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biosyent Inc in the market include pharmaceutical companies like Apotex Inc, Teva Pharmaceutical Industries Ltd, and Mylan N.V.
Biosyent Inc is a pharmaceutical company based in Canada. It was founded in 2004 and has since become a leader in the specialty pharmaceutical industry. The company focuses on acquiring or in-licensing niche pharmaceutical products, with a goal to provide reliable and effective therapeutic options to patients and healthcare professionals. Biosyent Inc has a successful track record of commercializing pharmaceutical products and has established a strong presence in the Canadian market. With a commitment to high-quality medications, Biosyent Inc continuously strives to meet the evolving healthcare needs of the population.
Biosyent Inc has achieved significant milestones since its inception. The company has successfully launched and commercialized multiple pharmaceutical and healthcare products in Canada. This includes obtaining regulatory approvals for important drugs, expanding their product portfolio, and establishing strategic partnerships with global pharmaceutical companies. Biosyent Inc has also demonstrated consistent revenue growth and increased market share, highlighting its strong performance in the industry. With their commitment to innovation and delivering high-quality products, Biosyent Inc continues to contribute to the advancement of healthcare and pharmaceuticals.
Biosyent Inc is primarily present in Canada and the United States.
Biosyent Inc is a pharmaceutical company that values innovation, sustainability, and customer-centricity. Their corporate philosophy revolves around providing high-quality, niche pharmaceutical products to meet the evolving healthcare needs of patients. With a focus on sourcing and licensing unique product opportunities, Biosyent Inc has built a strong reputation as a reliable partner within the healthcare industry. By utilizing their expertise in regulatory affairs and product commercialization, Biosyent Inc strives to improve patient outcomes while delivering value to their shareholders.
Analysts currently set an average price target of 16.83 CAD for the BioSyent stock (median: 16.83 CAD), implying +7.5 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the BioSyent stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BioSyent to generate revenue of 73.20 M CAD and earnings per share of 1.02 CAD.
Converted at the current exchange rate, the BioSyent share trades at 9.74 EUR (15.65 CAD).
The BioSyent share (RX.V) is listed on 2 stock exchanges, including: Toronto (RX.V).
Biosyent Inc is a pharmaceutical company headquartered in Canada that focuses on the development, marketing, and distribution of innovative products. The company specializes in medications in the areas of dermatology, gastroenterology, urology, and pain management. The business strategy of Biosyent Inc is to bring new products to the market that are needed by the growing number of patients and healthcare providers. In addition, the company also produces generics, which it offers at lower costs than the originals. Biosyent Inc aims to improve the lives of patients through better healthcare solutions. The company is active in various regions and works with partners in Canada, the US, and Europe. Through targeted investments and marketing initiatives, Biosyent Inc has managed to expand its reach and diversify its offerings. The company collaborates closely with physicians, pharmacies, and customers to tailor its offerings to their needs. In the field of dermatology, the company offers preparations for acne, eczema, psoriasis, and other skin problems. In gastroenterology, Biosyent Inc has developed medications that can be used to treat gastrointestinal diseases such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis. In urology, the company offers a solution for erectile dysfunction, and in pain management, it provides effective opioid antagonists in the form of nasal sprays and sublingual tablets. In addition to pharmaceutical products, Biosyent Inc also offers diagnostics and a solution for measuring urine flow. To further improve its products, the company also invests in researching new technologies and therapy forms. The company has a strong research and development department that works closely with the marketing and sales departments. Biosyent Inc strategically invests in the search for new active ingredients and solutions to continue offering its customers innovative products. Furthermore, the company works on optimizing its production processes and increasing its efficiency. The divisions of Biosyent Inc include: - Dermatology - Gastroenterology - Urology - Pain management Biosyent Inc. focuses on diversifying its offerings and producing innovative products that meet the needs of patients. Through the use of new technologies and procedures, the company aims to continue growing and strengthening its position in the market.
The expected revenue of BioSyent is 73.20 M CAD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioSyent is 11.81 M CAD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioSyent is currently 15.36. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioSyent stock.
The price-to-sales ratio (P/S) of BioSyent is currently 2.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioSyent stock.
The Eulerpool Quality Score for BioSyent is 8/10.
The ISIN of BioSyent is CA0906901081. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioSyent is A1J6DY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioSyent is RX.V. The ticker symbol is used to trade BioSyent shares on the stock exchange.
Over the past 12 months, BioSyent paid a dividend of 0.20 CAD . This corresponds to a dividend yield of about 1.28 %. For the coming 12 months, BioSyent is expected to pay a dividend of 0.25 CAD.
The current dividend yield of BioSyent is 1.28 %.
BioSyent pays a dividend, distributed in the months of , , , .
BioSyent paid dividends every year for the past 4 years.
For the upcoming 12 months, dividends amounting to 0.25 CAD are expected. This corresponds to a dividend yield of 1.57 %.
BioSyent is assigned to the 'Health' sector.
To receive the latest dividend of BioSyent from amounting to 0.06 CAD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, BioSyent distributed 0.18 CAD as dividends.
The dividends of BioSyent are distributed in CAD.
BioSyent stock
BioSyent Peer Group
BioSyent Ticker
BioSyent FIGI
All fundamentals and in-depth analysis of BioSyent
Our stock analysis for BioSyent stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioSyent. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.